PharmaShots | Incisive News in 3 Shots

Subscribe Now

Rheumatoid Arthritis

Celltrion Receives IND Approval for P-III Trial of CT-P47 (biosimilar, tocilizumab) to Treat Rheumatoid Arthritis in Poland

Celltrion Receives IND Approval for P-III Trial of CT-P47 (biosimilar, tocilizumab) to Treat Rheumatoid Arthritis in Poland

July 19, 2022

Biogen and Bio-Thera Solutions Present Results of BIIB800 (biosimilar, tocilizumab) in P-III Trial for Rheumatoid Arthritis at EULAR 2022

Biogen and Bio-Thera Solutions Present Results of BIIB800 (biosimilar, tocilizumab) in P-III Trial for Rheumatoid Arthritis at EUL...

June 6, 2022

Samsung Bioepis Presents Results of SB5 (biosimilar, adalimumab) in P-I and (PROPER) Study for Rheumatoid Arthritis and Other Inflammatory Diseases at EULAR 202

Samsung Bioepis Presents Results of SB5 (biosimilar, adalimumab) in P-I and (PROPER) Study for Rheumatoid Arthritis and Other Infl...

June 1, 2022

Horizon Reports Results of HZN-4920 in P-II Study for Rheumatoid Arthritis

Horizon Reports Results of HZN-4920 in P-II Study for Rheumatoid Arthritis

May 4, 2022

Abivax Reports One-Year Maintenance Results of ABX464 in P-IIa Trial for the Treatment with Rheumatoid Arthritis

Abivax Reports One-Year Maintenance Results of ABX464 in P-IIa Trial for the Treatment with Rheumatoid Arthritis

March 10, 2022

Samsung Bioepis and Organon’s Reports US FDA’s Acceptance of sBLA for Review of SB5 (biosimilar, adalimumab) for Rheumatoid Arthritis

Samsung Bioepis and Organon’s Reports US FDA’s Acceptance of sBLA for Review of SB5 (biosimilar, adalimumab) for Rheumatoid Arthri...

January 5, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us